...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Radiotherapy and oncology: Journal of the European Society for Therapeutic Radiology and Oncology >The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma.
【24h】

The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma.

机译：I-125 / Pd-103近距离放射线外照射对前列腺癌的作用。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND AND PURPOSE: To compare the biochemical outcomes of patients treated with Pd-103/I-125 brachytherapy alone vs. brachytherapy combined with external beam radiotherapy for early stage prostate carcinoma. METHODS: Brachytherapy monotherapy was used in 403 patients. Brachytherapy was combined with 45 Gy of external beam radiotherapy in 231 patients. Median follow-up was 58 months. To compare the biochemical outcomes of these two treatment approaches, patients were stratified into three relative risk groups: low risk, T(1)-T(2), Gleason 2-6/10, PSA< or =10.0; intermediate risk, T(3), Gleason 7-10/10, PSA>10.0 (one factor); high risk, T(3), Gleason 7-10/10, PSA>10.0 (two factors). RESULTS: The actuarial biochemical progression-free rate (bNED) for the entire 634 patients was 85% at 10 years. The bNED outcomes by risk group for monotherapy vs. combined therapy respectively were: low risk, 94 vs. 87%; intermediate risk, 84 vs. 85%; high risk, 54 vs. 62%. These differences did not reach statistical significance for any risk group. Rectal morbidity was slightly greater in the combined treatment patients. CONCLUSION: Although the addition of external beam irradiation to brachytherapy is conceptually appealing for patients with higher risk prostate carcinoma, we were unable to demonstrate a benefit. Whether this is because of patient selection biases within the risk groupings, an artefact of retrospective review, or because external radiotherapy does not offer additional benefit is uncertain.
机译：背景与目的：比较单独的Pd-103 / I-125近距离放射治疗与近距离放射治疗结合外照射治疗在早期前列腺癌中的疗效。方法：近距离治疗单药治疗403例。近距离放射疗法与45 Gy外部束放射疗法相结合，治疗了231例患者。中位随访时间为58个月。为了比较这两种治疗方法的生化结果，将患者分为三个相对风险组：低风险，T（1）-T（2），Gleason 2-6 / 10，PSA <或= 10.0;中度风险，T（3），格里森7-10 / 10，PSA> 10.0（一个因素）;高风险，T（3），格里森（Gleason）7-10 / 10，PSA> 10.0（两个因素）。结果：整个634例患者在10年时的精算生化无进展率（bNED）为85％。风险组分别采用单一疗法和联合疗法的bNED结果为：低风险，分别为94％和87％;中度风险：84％与85％;高风险，分别为54％和62％。这些差异对于任何风险组均未达到统计学意义。联合治疗患者的直肠发病率略高。结论：尽管在近距离放射治疗中增加外部束照射在概念上对高风险前列腺癌患者具有吸引力，但我们无法证明其获益。尚不确定这是由于风险人群中的患者选择偏见，回顾性检查的假象，还是由于外部放射治疗无法提供额外的益处尚不确定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号